Barinthus Biotherapeutics (Barinthus Biotherapeutics) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics Debt-to-Equity?

Barinthus Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.79 Mil. Barinthus Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.19 Mil. Barinthus Biotherapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $186.78 Mil. Barinthus Biotherapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Barinthus Biotherapeutics's Debt-to-Equity or its related term are showing as below:

BRNS' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.24 Med: 0.03 Max: 0.07
Current: 0.07

During the past 5 years, the highest Debt-to-Equity Ratio of Barinthus Biotherapeutics was 0.07. The lowest was -1.24. And the median was 0.03.

BRNS's Debt-to-Equity is ranked better than
66.6% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs BRNS: 0.07

Barinthus Biotherapeutics Debt-to-Equity Historical Data

The historical data trend for Barinthus Biotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics Debt-to-Equity Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.08

-1.24

0.03

0.04

0.07

Barinthus Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.04	0.05	0.06	0.07	0.07

Competitive Comparison of Barinthus Biotherapeutics's Debt-to-Equity

For the Biotechnology subindustry, Barinthus Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's Debt-to-Equity falls into.

Barinthus Biotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Barinthus Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.785	+	11.191)	/	186.784
	=	0.07

Barinthus Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.785	+	11.191)	/	186.784
	=	0.07

Barinthus Biotherapeutics (NAS:BRNS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Barinthus Biotherapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Barinthus Biotherapeutics (Barinthus Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, Didcot, GBR, OX11 0DF

Website

https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Executives

Joseph Scheeren	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright	director, officer: Chief Executive Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier	officer: Chief Scientific Officer	C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown	officer: Chief Financial Officer	VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths	officer: Chief Business Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis	officer: Chief Operating Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall	officer: Chief Medical Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans	officer: Chief Scientific Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov	officer: Chief Financial Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE